Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
Renal cancer PDO
A renal cancer PDO system for evaluating responses to targeted and immune therapies using apoptosis and immune-cell activation readouts.
PAX8CD10CD3CD8CD107a
Model source
Patient renal tumor tissue
Culture / format
PDO · Immune co-culture study format
Supporting evidence
TRiCBIO renal cancer PDO study data
Model characterization
How the model is established and characterized
Source-tissue and organoid imaging plus lineage/identity markers characterize the model; functional readouts are selected for the candidate mechanism and study objective.
View imageModel confirmation: source tissue, PDO histology and bright-field views establish the model context before treatment studies.
TRiCBIO RCC PDO 2.0 study data
View imageApoptosis readouts: flow plots compare Annexin V/PI distributions across control, targeted, immune and combination conditions to guide cell-death endpoints and replication.
TRiCBIO RCC PDO 2.0 study data
Immune readouts: CD3/CD8 flow cytometry is interpreted with apoptosis measurements to compare cell-death and immune changes across the same treatment conditions.
TRiCBIO RCC PDO 2.0 study dataView the complete study figure set
View imageStudy planning
From study objective to model and assay plan
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Integrate renal-tumor identity, apoptosis and immune change
Renal cancer programs may span targeted agents, mTOR-associated regimens and immunotherapy. Establish source-tissue and PDO identity before comparing treatment conditions with consistent controls, apoptosis and immune readouts.
Review pathology and sample context
Confirm renal cancer pathology, sampling site, prior treatment, sample state and available source-tissue records.
Confirm identity and study QC
Compare source-tissue H&E, PDO bright-field and PDO H&E, adding study-relevant markers such as PAX8 and CD10 before treatment studies.
Design conditions around mechanism
Set dose, timing, single-agent groups and controls around targeted, mTOR-associated, ICB or combination mechanisms, then compare results using consistent analysis criteria.
Interpret apoptosis and immune results together
Integrate Annexin V/PI, CD3/CD8/CD107a flow, histology and viability to distinguish tumor-cell death, immune-population shifts and sample variation.
Research applications
Recommended applications
- Targeted and mTOR-related regimens
- ICB studies
- Apoptosis and immune-cell activation
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
PAX8CD10CD3CD8CD107a
Available assays
- Annexin V
- IHC / IF
- Flow cytometry
- Viability
QC approach
QC combines tissue identity, morphology, apoptosis and immune functional readouts.
Study & delivery
Model characterization, treatment data and reporting
Choose a supplied model or a TRiCBIO-run intervention study. Typical deliverables include functional data and a project report.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a renal cancer PDO study
Tumor type, sample status, candidate profile and comparison endpoints determine the culture format, controls, assay panel and deliverables for the renal cancer PDO.